Jazz Pharmaceuticals plc [JAZZ] stock prices are up 0.12% to $169.73 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The JAZZ shares have gain 4.60% over the last week, with a monthly amount glided 20.32%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Jazz Pharmaceuticals plc [NASDAQ: JAZZ] stock has seen the most recent analyst activity on November 24, 2025, when UBS downgraded its rating to a Neutral but kept the price target unchanged to $188 for it. Previously, Deutsche Bank started tracking the stock with Buy rating on July 15, 2025, and set its price target to $152. On March 07, 2025, upgrade upgraded it’s rating to Buy and revised its price target to $179 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral. Wells Fargo upgraded its rating to an Overweight and raised its price target to $170 on February 13, 2025. Morgan Stanley upgraded its rating to Overweight for this stock on December 12, 2024, and upped its price target to $175. In a note dated June 05, 2024, Goldman initiated a Buy rating and provided a target price of $169 on this stock.
The stock price of Jazz Pharmaceuticals plc [JAZZ] has been fluctuating between $95.49 and $182.99 over the past year. Currently, Wall Street analysts expect the stock to reach $190.43 within the next 12 months. Jazz Pharmaceuticals plc [NASDAQ: JAZZ] shares were valued at $169.73 at the most recent close of the market. An investor can expect a potential return of 12.2% based on the average JAZZ price forecast.
Analyzing the JAZZ fundamentals
The Jazz Pharmaceuticals plc [NASDAQ:JAZZ] reported sales of 4.16B for trailing twelve months, representing a surge of 6.74%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -0.12%, Pretax Profit Margin comes in at -0.17%, and Net Profit Margin reading is -0.09%. To continue investigating profitability, this company’s Return on Assets is posted at -0.03, Equity is -0.09 and Total Capital is -0.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.27.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 168.09 points at the first support level, and at 166.46 for the second support level. However, for the 1st resistance point, the stock is sitting at 170.80, and for the 2nd resistance point, it is at 171.88.
Ratios To Look Out For
It’s worth pointing out that Jazz Pharmaceuticals plc [NASDAQ:JAZZ]’s Current Ratio is 1.65. Also, the Quick Ratio is 1.44, while the Cash Ratio stands at 0.58. Considering the valuation of this stock, the price to sales ratio is 2.48, the price to book ratio is 2.60.
Transactions by insiders
Recent insider trading involved Henderson Mary Elizabeth, SVP, Technical Operations, that happened on Dec 09 ’25 when 2238.0 shares were sold. Officer, MARY ELIZABETH HENDERSON completed a deal on Dec 09 ’25 to buy 2238.0 shares. Meanwhile, SVP, Chief Accounting Officer Carr Patricia sold 4660.0 shares on Dec 05 ’25.
